Zacks Research Has Positive Estimate for Amarin Q1 Earnings

Amarin Co. plc (NASDAQ:AMRN) – Equities research analysts at Zacks Research increased their Q1 2025 earnings per share (EPS) estimates for Amarin in a research note issued on Thursday, April 24th. Zacks Research analyst R. Department now forecasts that the biopharmaceutical company will post earnings of ($1.23) per share for the quarter, up from their previous estimate of ($1.40). The consensus estimate for Amarin’s current full-year earnings is ($0.15) per share. Zacks Research also issued estimates for Amarin’s Q2 2025 earnings at ($1.12) EPS, Q3 2025 earnings at ($1.25) EPS, Q4 2025 earnings at ($2.23) EPS, FY2025 earnings at ($5.84) EPS, Q1 2026 earnings at ($0.97) EPS, Q2 2026 earnings at ($1.05) EPS, Q3 2026 earnings at ($1.38) EPS, Q4 2026 earnings at ($1.72) EPS and FY2026 earnings at ($5.11) EPS.

Other equities analysts have also issued reports about the stock. The Goldman Sachs Group reduced their target price on shares of Amarin from $20.00 to $7.00 and set a “sell” rating for the company in a research note on Thursday, April 17th. StockNews.com assumed coverage on Amarin in a research report on Wednesday, April 16th. They set a “sell” rating for the company.

Amarin Stock Down 1.1 %

Amarin stock opened at $10.32 on Monday. The company has a 50 day moving average of $9.59 and a 200-day moving average of $10.36. Amarin has a twelve month low of $7.08 and a twelve month high of $20.60. The stock has a market capitalization of $211.91 million, a PE ratio of -114.67 and a beta of 1.38.

Amarin (NASDAQ:AMRN) last released its quarterly earnings data on Wednesday, March 12th. The biopharmaceutical company reported ($2.40) earnings per share for the quarter, missing the consensus estimate of ($1.20) by ($1.20). Amarin had a negative net margin of 16.33% and a negative return on equity of 7.22%. The business had revenue of $62.31 million for the quarter, compared to the consensus estimate of $32.37 million.

Institutional Inflows and Outflows

Several large investors have recently added to or reduced their stakes in the business. Waterfront Wealth Inc. boosted its stake in shares of Amarin by 1.3% during the 1st quarter. Waterfront Wealth Inc. now owns 2,514,615 shares of the biopharmaceutical company’s stock worth $1,127,000 after buying an additional 32,849 shares during the last quarter. Stonepine Capital Management LLC bought a new stake in Amarin during the fourth quarter worth about $55,000. BNP Paribas Financial Markets boosted its position in Amarin by 3.0% during the fourth quarter. BNP Paribas Financial Markets now owns 1,340,920 shares of the biopharmaceutical company’s stock valued at $650,000 after purchasing an additional 39,452 shares during the last quarter. AXA S.A. bought a new position in Amarin in the fourth quarter valued at approximately $480,000. Finally, Mercer Global Advisors Inc. ADV acquired a new position in shares of Amarin during the 4th quarter worth approximately $171,000. Institutional investors and hedge funds own 22.25% of the company’s stock.

About Amarin

Amarin Corporation plc, a pharmaceutical company, engages in the development and commercialization of therapeutics for the treatment of cardiovascular diseases in the United States, European countries, Canada, Lebanon, and the United Arab Emirates. The company offers VASCEPA, a prescription-only omega-3 fatty acid product, used as an adjunct to diet for reducing triglyceride levels in adult patients with severe hypertriglyceridemia.